Telomir Pharmaceuticals Inc

For the period ended Mar 31, 2024. Filed May 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

TELO$0.71-9.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Financial Statements (unaudited) Condensed Balance Sheets as of March 31, 2024 and December 31, 2023

TELOMIR PHARMACEUTICALS, INC****.**

** CONDENSED BALANCE SHEETS**

AS OF MARCH 31, 2024 AND DECEMBER 31, 2023

	March 31, (Unaudited)	December 31,
	2024	2023
ASSETS
Current assets:
Cash	$3,274,314	$1,231
Deferred offering costs	-	303,281
Prepaid expenses	98,808	713
Due from related parties	130,000	130,000
Total current assets	3,503,122	435,225
Deferred Financing Costs	-	4,338,543
Total assets	$3,503,122	$4,773,768
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Trade accounts payable and accrued liabilities	$478,650	$707,187
Due to related parties	7,902	527,377
Related party line of credit	-	101,000
Total current liabilities	486,552	1,335,564
Total liabilities	486,552	1,335,564
Stockholders’ Equity (Deficit)
Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding.	-	-
Common Stock, no par value; 300,000,000 shares authorized, 29,609,814 and 28,609,814 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	-	-
Additional paid-in capital	23,335,319	17,502,346
Accumulated deficit	(20,318,749)	(14,064,142)
Total stockholders’ equity	3,016,570	3,438,204
Total liabilities and stockholders’ equity	$3,503,122	$4,773,768

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.